Linda Pestano

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index1.3kcitations44works0.82yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

MicroRNA in disease regulation(15), Cutaneous lymphoproliferative disorders research(8), Protein Degradation and Inhibitors(7), RNA Interference and Gene Delivery(6), Pain Management and Opioid Use(4)

Publications44 total

Appendix: Formulation development and a Phase 1 clinical study of PF614-MPAR, an oxycodone prodrug with oral opioid overdose protection
Journal of Opioid Management·2026Open Access
Formulation development and a Phase 1 clinical study of PF614-MPAR, an oxycodone prodrug with oral opioid overdose protection
Journal of Opioid Management·2026Open Access
Intranasal Human Abuse Potential of PF614: A Novel ‘Next Generation’ Trypsin Activated Abuse Protected (TAAP) Opioid
Drug and Alcohol Dependence·2024
Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers
Clinical and Translational Science·2024· 3 citedOpen Access
Figure S1 from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S3 from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S2 from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S3 from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Materials and Methods from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Materials and Methods from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S1 from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Table S1 from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Table S1 from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S2 from Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
EBioMedicine·2022· 108 citedOpen Access
A lung targeted miR-29 Mimic as a Therapy for Pulmonary Fibrosis
2021· 7 citedOpen Access
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Clinical Cancer Research·2020· 145 citedOpen Access
Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study
Nucleic Acid Therapeutics·2020· 147 cited
page 1 of 3Next →

Frequent Co-authors

Anita G. Seto(20), Aimee L. Jackson(20), Diana M. Escolar(17), Lauren Pinter‐Brown(16), Xuan Beatty(14), Eleni Anastasiadou(13), Melanie Hermreck(13), Maud-Emmanuelle Gilles(13), Dina Stroopinsky(13), Cinzia Marchese(13), David Avigan(13), Frank J. Slack(13), Pankaj Trivedi(12), Brent Dickinson(9), Paul Rubin(8), William S. Marshall(7), Christiane Querfeld(6), Judy Ruckman(6), Tomislav Dragovich(5), Theresa Pacheco(5)